Products & Innovation / Pipeline
Everything we’re building for CNS cancer.
CNSide®, our cerebrospinal fluid (CSF) assay, is commercially available and in clinical use across the U.S. The investigational radiotherapeutic REYOBIQ™ (rhenium Re 186 obisbemeda) is in three active ReSPECT™ trials. The data layer compounds behind both.
Our full pipeline at a glance.
Integrating precision diagnostics, targeted therapeutics, and data insights to improve outcomes for patients with central nervous system (CNS) cancers.
CNSide®
CNSide®
Stage: Commercial
Stage: Commercial
Stage: Launching soon
REYOBIQ™
REYOBIQ™
Stage: Phase 2
Stage: Phase 2
Stage: Phase 1
Stage: In development
Where the programs stand.
3
3 active ReSPECT™ trials, advancing REYOBIQ™ across recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer.
$24M
$24M in non-dilutive National Cancer Institute (NCI), Cancer Prevention and Research Institute of Texas (CPRIT), and Department of Defense (DoD) support behind the therapeutic program.
5
5 FDA designations. U.S. FDA has granted REYOBIQ™ five regulatory designations: Orphan Drug Designation for glioblastoma; Orphan Drug Designation for leptomeningeal metastases in breast cancer and lung cancer patients; and Fast Track Designation for leptomeningeal metastases and recurrent glioblastoma.
Innovative technologies that expand possibilities for CNS cancers.
The focus stays on the CNS. The underlying radiotherapeutic technology potential reaches further.